IBDEI1RV ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,31681,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,31681,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,31681,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,31682,0)
 ;;=C92.50^^190^1943^12
 ;;^UTILITY(U,$J,358.3,31682,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31682,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,31682,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,31682,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,31683,0)
 ;;=C94.40^^190^1943^15
 ;;^UTILITY(U,$J,358.3,31683,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31683,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,31683,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,31683,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,31684,0)
 ;;=C94.42^^190^1943^13
 ;;^UTILITY(U,$J,358.3,31684,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31684,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,31684,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,31684,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,31685,0)
 ;;=C94.41^^190^1943^14
 ;;^UTILITY(U,$J,358.3,31685,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31685,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,31685,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,31685,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,31686,0)
 ;;=D62.^^190^1943^16
 ;;^UTILITY(U,$J,358.3,31686,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31686,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,31686,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,31686,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,31687,0)
 ;;=C92.41^^190^1943^17
 ;;^UTILITY(U,$J,358.3,31687,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31687,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,31687,1,4,0)
 ;;=4^C92.41
 ;;^UTILITY(U,$J,358.3,31687,2)
 ;;=^5001802
 ;;^UTILITY(U,$J,358.3,31688,0)
 ;;=C92.40^^190^1943^18
 ;;^UTILITY(U,$J,358.3,31688,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31688,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,31688,1,4,0)
 ;;=4^C92.40
 ;;^UTILITY(U,$J,358.3,31688,2)
 ;;=^5001801
 ;;^UTILITY(U,$J,358.3,31689,0)
 ;;=D56.0^^190^1943^19
 ;;^UTILITY(U,$J,358.3,31689,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31689,1,3,0)
 ;;=3^Alpha Thalassemia
 ;;^UTILITY(U,$J,358.3,31689,1,4,0)
 ;;=4^D56.0
 ;;^UTILITY(U,$J,358.3,31689,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,31690,0)
 ;;=D63.1^^190^1943^21
 ;;^UTILITY(U,$J,358.3,31690,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31690,1,3,0)
 ;;=3^Anemia in Chronic Kidney Disease
 ;;^UTILITY(U,$J,358.3,31690,1,4,0)
 ;;=4^D63.1
 ;;^UTILITY(U,$J,358.3,31690,2)
 ;;=^332908
 ;;^UTILITY(U,$J,358.3,31691,0)
 ;;=D63.0^^190^1943^22
 ;;^UTILITY(U,$J,358.3,31691,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31691,1,3,0)
 ;;=3^Anemia in Neoplastic Disease
 ;;^UTILITY(U,$J,358.3,31691,1,4,0)
 ;;=4^D63.0
 ;;^UTILITY(U,$J,358.3,31691,2)
 ;;=^321978
 ;;^UTILITY(U,$J,358.3,31692,0)
 ;;=D63.8^^190^1943^20
 ;;^UTILITY(U,$J,358.3,31692,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31692,1,3,0)
 ;;=3^Anemia in Chronic Diseases Classified Elsewhere
 ;;^UTILITY(U,$J,358.3,31692,1,4,0)
 ;;=4^D63.8
 ;;^UTILITY(U,$J,358.3,31692,2)
 ;;=^5002343
 ;;^UTILITY(U,$J,358.3,31693,0)
 ;;=C22.3^^190^1943^23
 ;;^UTILITY(U,$J,358.3,31693,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31693,1,3,0)
 ;;=3^Angiosarcoma of Liver
 ;;^UTILITY(U,$J,358.3,31693,1,4,0)
 ;;=4^C22.3
 ;;^UTILITY(U,$J,358.3,31693,2)
 ;;=^5000936
 ;;^UTILITY(U,$J,358.3,31694,0)
 ;;=D61.9^^190^1943^24
